Table 2.

Summary of drug action on 5-HT₂ receptors.

Drug / Receptor	5-HT2A	5-HT2B	5-HT2C	Model (Ref)
2C-B	partial agonist ∼ 5–10 % (weak response for PLC and PLA2 pathways)	-	partial agonist ∼ 40–50 % (PLC and PLA2 pathways)	CHO cells expressing human 5-HT2A or 5-HT2C receptors [28]
2C-N	partial agonist ∼ 20 % (PLA2 pathway)	-
2C-D 2C-I	partial agonist ∼ 15–30 % (PLC and PLA2 pathways)	-
2C-C 2C-D 2C-E 2C‐T‐2	full agonist ∼ 65–125 % (PLC and PLA2 pathways)	-	full agonist ∼ 80–100 % (PLC pathway)	HEK cells expressing the corresponding human 5-HT receptors [29]
2C-I	full agonist ∼ 80 % (PLC pathway) antagonist ∼ 30 % (PLA2 pathway)
25D-NBOMe 25E-NBOMe 25H-NBOMe 25N-NBOMe	full agonist ∼ 85–95 % (PLC pathway)	partial agonist ∼ 40–50 % (PLC pathway)	full agonist ∼ 90–100 % (PLC pathway)	HEK cells expressing the corresponding human 5-HT receptors [24]
2C‐T‐4 2C‐T‐7	partial agonist ∼ 50–60 %	partial agonist ∼ 45–75 %	-	HEK 293 cells expressing the corresponding human 5-HT2B receptors; mouse embryonic fibroblasts expressing the human 5-HT2A receptor [27]
2C-B, 2C-C, 2C-D, 2C-E, 2C-I, 2C-N, 2C‐T‐2, 2C‐T‐4, 2C‐T‐7, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25I-NBOMe, 25N-NBOMe, 25T2-NBOMe, 25T4-NBOMe, 25T7-NBOMe	partial agonist ∼ 40–90 %	partial agonist ∼ 45–90 %	-	NIH-3T3 expressing the human 5-HT2A receptors; HEK293 cells expressing the human 5-HT2B receptors [25]
2C-C 2C-I 25C-NBOMe 25I-NBOMe	full agonist ∼ 90–110 %	-	partial agonist ∼ 30–70 %	HEK 293 cells expressing the corresponding human 5-HT2A and 5-HT2C receptors [23]